Table 1.
The patient characteristics
| Gender | |
| Male | 139 |
| Female | 115 |
| Age (years) | |
| Median (range) | 66 (26–86) |
| Location of primary tumor | |
| Colon | 131 |
| Rectum | 123 |
| Tumor depth | |
| T1-3 | 176 |
| T4 | 77 |
| Histological type | |
| Well, moderately | 234 |
| Poorly, mucinous | 19 |
| Lymphatic involvement | |
| Negative | 47 |
| Positive | 184 |
| Venous involvement | |
| Negative | 170 |
| Positive | 68 |
| Number of lymph node metastases | |
| 0 | 85 |
| 1–3 | 116 |
| ≥4 | 53 |
| Stage | |
| II | 85 |
| III | 169 |
| Regimen of chemotherapy | |
| Oral 5-FU monotherapy | 178 |
| CapeOX | 19 |
| FOLFOX | 11 |
| None | 46 |
| Median value of indicators of the preoperative systemic inflammatory response (range) | |
| NLR | 2.26 (0.87–10.24) |
| CRP (mg/dl) | 0.11 (0.01–13.99) |
| Preoperative serum albumin level (g/dl) | |
| Median (range) | 4.1 (2.6–4.8) |
| Median value of indicators of the postoperative systemic inflammatory response (range) | |
| NLR | 1.82 (0.18–10.11) |
| CRP (mg/dl) | 0.09 (0.01–17.09) |
| Postoperative serum albumin level (g/dl) | |
| Median (range) | 4.0 (3.0–4.7) |
| The number of days from operation until the first visit after leaving the hospital | |
| Median (interquartile range) | 29 (23–36) |
5-FU 5-fluorouracil, CapeOX capecitabine plus oxaliplatin, FOLFOX 5-fluorouracil/leucovorin plus oxaliplatin, NLR neutrophil-to-lymphocyte ratio, CRP C-reactive protein